论文信息 - Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia - 字舞流文

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

K. Döhner | H. Döhner | V. Gaidzik | M. Heuser | F. Thol | K. Götze | T. Holderried | S. Scholl | U. Germing | G. Kobbe | J. Chemnitz | U. Holtick | R. Haas | M. Verbeek | U. Platzbecker | Josephin Schröder | S. Krause | M. Bornhäuser | U. Kaiser | M. Hanoun | W. Krüger | V. Vucinic | M. Stelljes | C. Schliemann | Kathrin Koch | J. Schetelig | Lea Henning | J. Middeke | S. Kraus | C. Röllig | M. Hänel | M. Lauseker | T. Schroeder | T. Sauer | F. Stölzel | K. Schäfer-Eckart | N. Alakel | K. Sockel | L. Fransecky | M. Wass | E. Wagner-Drouet | Oliver Kriege | C. Rautenberg | A. Morgner | C. Jehn | M. Röhnert | J. Unglaub | Charlotte Neuerburg | Julia Severmann | O. Kriege | Maxi Wass | V. Vučinić | K. Schäfer‐Eckart | Lars Fransecky

[1] J. Cortes,et al. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. , 2021, Blood advances.

[2] E. Colado,et al. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia , 2021, Leukemia.

[3] F. Pasquier,et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. , 2021, Blood advances.

[4] L. Pagano,et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program , 2020, Blood Cancer Journal.

[5] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[6] J. Cortes,et al. Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). , 2019, Blood.

[7] B. Stevens,et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. , 2019, Blood advances.

[8] L. Mayer,et al. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties , 2019, International journal of nanomedicine.

[9] M. Heuser,et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome , 2018, Leukemia.

[10] Robert K. Stuart,et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11] L. Bullinger,et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) , 2017, Annals of Hematology.

[12] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[13] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[14] M. Nørgaard,et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[16] L. Möllgård,et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry , 2015, American journal of hematology.

[17] D. Neuberg,et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[18] G. Ehninger,et al. Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia , 2013, Leukemia.

[19] G. Juliusson,et al. Acute myeloid leukemia in the real world: why population-based registries are needed. , 2012, Blood.

[20] K. Döhner,et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.

[21] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22] H. Deeg,et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23] M. Turner,et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.